Biogen’s Q3 Earnings: Key Analyst Questions on LEQEMBI & Growth
Biogen delivered a strong third-quarter performance, exceeding Wall Street’s revenue and profit expectations, driven by robust sales of recently launched products and continued strength within its multiple sclerosis portfolio. The company’s management attributed substantial growth to LEQEMBI, SKYCLARYS, and ZURZUVAE, which demonstrated significant year-over-year gains. CEO Christopher Viehbacher highlighted this positive momentum, noting that more than half of the products launched this year had already offset the decline in the multiple sclerosis segment over the year-to-date period. Despite ongoing challenges related to generic competition, particularly in Europe for the MS franchise, Biogen’s ability to grow new products and maintain a disciplined approach to cost management contributed to an improved operating margin. The company currently trades at $152.95, up from $148.19 just before the earnings release.
The third-quarter results showcased several key financial metrics. Revenue reached $2.53 billion, representing a 2.8% year-over-year increase, surpassing analysts’ estimates of $2.34 billion. Adjusted earnings per share (EPS) amounted to $4.81, exceeding expectations of $3.88, resulting in an impressive 23.9% beat. Furthermore, adjusted EBITDA reached $1.10 billion, a 43.5% margin, surpassing analyst estimates of $875.5 million, demonstrating a 25.9% beat. These figures underscore Biogen’s operational efficiency and effective product portfolio management.
During the earnings call, management addressed several critical questions from analysts, offering valuable insights into the company’s strategic direction and future prospects. Umer Raffat from Evercore inquired about the potential commercial impact of the EVOKE trial on LEQEMBI and whether Biogen would consider collaborations for new treatment approaches. Viehbacher responded that outcomes could expand primary care use but noted the company’s ongoing evaluation of options as data emerges. Evan Seigerman from BMO Capital Markets questioned how Biogen’s renewed focus on immunology could drive growth, prompting Viehbacher to state that the company’s MS experience is directly applicable to new immunology indications and emphasized the long-term opportunity to build a broader portfolio. Salveen Richter from Goldman Sachs sought confidence in the late-stage pipeline and the rationale for early-stage business development, which Viehbacher cited as strong Phase II data for assets like felzartamab and a more disciplined progression from “moonshots” to derisked late-stage programs. Brian Abrahams from RBC Capital Markets inquired about early uptake and access for LEQEMBI’s subcutaneous maintenance formulation, to which Alisha Alaimo, President and Head of North America, reported positive feedback and anticipated gradual, meaningful adoption as providers and payers adapt. Paul Matteis from Stifel asked about the challenges of commercializing treatments for asymptomatic Alzheimer’s patients, given diagnostic and capacity constraints, to which Alaimo explained that advances in blood-based biomarkers and streamlined care pathways should enable increased diagnosis and treatment rates over time.
Looking ahead, Biogen’s management team is concentrating on key developments. StockStory’s research team will closely monitor the pace of commercial adoption for LEQEMBI’s subcutaneous and at-home formulations, progress on reimbursement and geographic expansion for SKYCLARYS and other launches, and advancement of key Phase III pipeline programs including litifilimab and BIIB080. Continued execution on cost management and the impact of generic pressures in Europe will also remain a significant area of focus. The company is actively navigating these multifaceted challenges while simultaneously capitalizing on its innovative product portfolio and strategic growth initiatives. Biogen currently holds a market capitalization of $22.51 billion.
